

| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Total Revenue | 1,670.37 | 1,827.13 | 1,670.95 | 1,543.08 | 1,244.64 |
| Total Expenses | 1,745.74 | 1,702.86 | 1,478.15 | 1,306.51 | 1,112.65 |
| Profit Before Tax | -74.37 | 135.80 | 192.79 | 236.57 | 132 |
| Profit After Tax | -77.95 | 97 | 142.25 | 154.80 | 93.05 |
| Operating Profit After Depreciation | -9.14 | 162.29 | 217.82 | 250.71 | 154.26 |
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Fixed Assets | 1,041.30 | 976.23 | 736.46 | 623.82 | 613.01 |
| Total Non Current Assets | 1,428.58 | 1,190.06 | 844.63 | 712.47 | 692.54 |
| Total Current Assets | 1,001.34 | 954.67 | 813.57 | 773.62 | 622.53 |
| Total Assets | 2,429.91 | 2,144.73 | 1,658.20 | 1,486.09 | 1,315.06 |
| Total Shareholder's Fund | 1,022 | 1,109.90 | 1,028.25 | 904.64 | 768.99 |
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Net Cash From Operating Activities | 94.93 | 155.39 | 178.83 | 173.83 | 82.22 |
| Net Cash Used In Investing Activities | -339.11 | -431.89 | -208.17 | -121.41 | -66.69 |
| Net Cash Used In Financing Activities | 241.42 | 280.43 | 22.80 | -44.37 | -29.87 |
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Total Revenue | 1,536.67 | 1,799.32 | 1,669.02 | 1,542.04 | 1,243.42 |
| Total Expenses | 1,545.04 | 1,657.62 | 1,477.43 | 1,305.81 | 1,112.06 |
| Profit Before Tax | -7.38 | 153.23 | 191.59 | 236.23 | 131.35 |
| Profit After Tax | -8.73 | 116.64 | 141.36 | 154.52 | 92.39 |
| Operating Profit After Depreciation | 48.26 | 178.51 | 216.62 | 250.37 | 153.57 |
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Fixed Assets | 798.80 | 754.28 | 719.66 | 623.70 | 612.89 |
| Total Non Current Assets | 1,245.69 | 1,060.39 | 847.21 | 714.79 | 694.62 |
| Total Current Assets | 955.47 | 900.21 | 812.47 | 772.78 | 621.95 |
| Total Assets | 2,201.16 | 1,960.61 | 1,659.67 | 1,487.57 | 1,316.57 |
| Total Shareholder's Fund | 1,103.36 | 1,126.62 | 1,027.02 | 904.30 | 768.93 |
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Net Cash From Operating Activities | 90.77 | 176.78 | 178.79 | 173.55 | 82.17 |
| Net Cash Used In Investing Activities | -259.79 | -301.70 | -208.51 | -121.41 | -66.70 |
| Net Cash Used In Financing Activities | 168.62 | 122.40 | 22.81 | -44.37 | -29.83 |
| Particulars (in ₹ Cr.) | 2025-09 | 2025-06 | 2025-03 | 2024-12 | 2024-09 |
|---|---|---|---|---|---|
| Total Revenue | 484.67 | 439.67 | 390.21 | 410.55 | 432.66 |
| Total Expenses | 441.62 | 422.14 | 390.99 | 398.52 | 392.41 |
| Profit Before Tax | -13.53 | -36.66 | -45.52 | -30.96 | -4.84 |
| Profit After Tax | -9.21 | -36.35 | -41.34 | -28.40 | -10.01 |
| Operating Profit after Depreciation | 43.81 | 19.16 | 1.24 | 12.88 | 41.81 |
| Particulars (in ₹ Cr.) | 2025-09 | 2025-06 | 2025-03 | 2024-12 | 2024-09 |
|---|---|---|---|---|---|
| Total Revenue | 442.12 | 392.53 | 347.25 | 372.98 | 396.53 |
| Total Expenses | 388.73 | 377.70 | 343.79 | 352.84 | 343.66 |
| Profit Before Tax | 9.76 | -28.40 | -30.90 | -13.36 | 17.38 |
| Profit After Tax | 15.05 | -28.06 | -26.24 | -10.23 | 12.79 |
| Operating Profit after Depreciation | 59.93 | 20.41 | 9.96 | 24.40 | 57.07 |
₹0.2/Share
| Company | Price | Market Cap (in Cr) |
|---|---|---|
| Sun Pharmaceutical Industries Ltd | ₹1,763.70 | ₹4,23,170.71 |
| Divis Laboratories Ltd | ₹6,523.25 | ₹1,73,171.79 |
| Torrent Pharmaceuticals Ltd | ₹3,816.75 | ₹1,29,170.36 |
| Cipla Ltd | ₹1,536.25 | ₹1,24,093.85 |
| Dr Reddys Laboratories Ltd | ₹1,244.50 | ₹1,03,868.61 |
| Fund Name | AUM |
|---|---|
| DSP Healthcare Fund | 2.87% |
| Nippon India Pharma Fund | 0.61% |
| HDFC Value Fund | 0.56% |
| DSP Multicap Fund | 0.49% |
| Tata India Innovation Fund | 0.49% |
Indoco Remedies' consolidated net loss narrowed to Rs 9.21 crore in Q2 FY26, compared with net loss of Rs 10.01 crore reported in Q2 FY25.
06 Nov 2025, 01:20 pm
On 6 November 2025
14 Oct 2025, 05:34 pm
30 Aug 2025, 11:44 am
On 11 September 2025
16 Aug 2025, 05:23 pm
Indoco Remedies rose 1.56% to Rs 296.15 after the company announced it had received final approval from the USFDA for its ANDA for Rivaroxaban tablets USP.
13 Aug 2025, 10:30 am

Get started with us today and
start building your wealth journey
*By clicking, I agree to the T&C and Whatsapp updates.

Get started with us today and
start building your wealth journey
*By clicking, I agree to the T&C and Whatsapp updates.

Congratulations,
Your Digital savings bank account opening journey is complete.